Complementary use of mpMRI and genomic testing in prostate cancer

In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.

“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.

Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.

Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.

“NSD2 is a cancer specific collaborator of the androgen receptor that essentially rewires its activity to support prostate cancer development," says Abhijit Parolia, PhD,

Patients who had mutations in the ERCC2, ATM, or RB1 genes were more than 5 times more likely to achieve a pathologic complete response following cisplatin-based chemotherapy.